IAM Issue 25

Owners or licensees of Australian
patents can be more bullish about
asserting them as they now have
less concerns over invalidation than
they would in many other countries

The failures of the US healthcare
market are exacerbated by a lack of
proper scrutiny of how VCs and other
investors in the sector evaluate IP

Those who are happy to continue
infringing IP rights once the
infringement becomes clear should
spend some time in jail. That would
concentrate minds a lot quicker than
mechanisms such as treble damages

In the developing knowledge
economy, the traditional divides that
separate universities from industry
are not sustainable

When it comes to understanding
what innovation rights such as
patents mean to public company
performance, CEOs are hiding in
plain sight

Indices based around rating the performance of quoted companies’
IP management and performance have been with us for a few years now.
Recent research shows the returns investors in one would have enjoyed
over a six month and one year period

It may not be worth putting intangibles on a balance sheet, but including
them in management commentaries is a completely different matter

Over the last few years, IBM has been a pivotal player in the development
of the patent system and in exploring the financial possibilities it offers.
Now Big Blue’s top IP lawyer is at it again

While many may see KSRas helpful to patent infringers, a close reading
of the decision reveals that the opposite may, in fact, be the case

The European Patent Conference was launched by the FFII, a group best
known for taking a hard line against software patents. By bringing different
stakeholders together, the hope is that dialogue will replace confrontation
as a way to build an effective European patent system

Although there was something for everyone in the KSRdecision, the real
winners will ultimately turn out to be members of the patent bar

When the CEO of Procter & Gamble decided that 50% of the company’s
products should be developed collaboratively, a new internal business
group was born. Seven years on, it is ensuring the boss is getting exactly
what he wants

Since first quarter 2006, most
pharma companies have increased
their patent portfolios. The
realignment is most closely tied to
differences in research intensity.

The new president of the
European Patent Office
will have her work cut out
as she tackles a number
of high-profile issues.
If Alison Brimelow plays
her cards right, however,
she could find allies at
the very top of Europe’s
political ladder

As companies strive for new
sources of value creation, with many
turning to their patent portfolios as
an asset base for exploitation,
CPA’s John Pryor looks at ways to
stay ahead of the competition

There is no doubting that these days
outsourcing is a multi-billion dollar
business. And it is not hard to see why,
as companies are in a position to save
substantial amounts of money when they
send out work to be done by third parties
at a fraction of the amount it would cost for
the same to be done in-house